Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.57 |
| ▸ | CCR3 | P51677 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 3/20 | 0.52 |
| ▸ | HTR2C | P28335 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2181082 | 0.91 | SIGMAR1 (0.57) | CCR3OPRM1HTR2ACYP1A2CYP3A4 | |
| SCHEMBL11478240 | 0.88 | SLC6A3 (0.55) | ACHECCR3OPRM1HTR2AHTR2C | |
| SCHEMBL2180441 | 0.83 | ACHE (0.54) | ACHECCR3CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL22455021 | 0.78 | ACHE (0.65) | ACHECCR3HTR2ASIGMAR1 | |
| SCHEMBL5534146 | 0.77 | ACHE (0.60) | ACHECCR3HTR2AHTR2CKDM4E | |
| SCHEMBL7384861 | 0.77 | SLC6A3 (0.50) | ACHECCR3HTR2AHTR2CSLC6A3 | |
| SCHEMBL6423692 | 0.77 | ACHE (0.60) | ACHECCR3HTR2AHTR2CKDM4E | |
| SCHEMBL5537485 | 0.77 | ACHE (0.60) | ACHECCR3HTR2AHTR2CKDM4E | |
| SCHEMBL6403439 | 0.77 | ACHE (0.60) | ACHECCR3HTR2AHTR2CKDM4E | |
| SCHEMBL7724029 | 0.77 | LTA4H (0.61) | ACHECCR3HTR2AHTR2CKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2351738-A1 | PROCESS FOR PRODUCING 1-SUBSTITUTED TRANS-4-(SUBSTITUTED AMINO)PIPERIDIN-3-OL | Sumitomo Chemical Company, Limited (JP) | 2011-08-03 | — | — | EP | disclosed |
| US-20110172431-A1 | PROCESS FOR PRODUCING 1-SUBSTITUTED TRANS-4-(SUBSTITUTED AMINO) PIPERIDIN-3-OL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110166357-A1 | METHOD FOR PRODUCING N-SUBSTITUTED-TRANS-4-AZIDOPIPERIDINE-3-OL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166357-A1 | METHOD FOR PRODUCING N-SUBSTITUTED-TRANS-4-AZIDOPIPERIDINE-3-OL | RPS27L, OSGEP, RPLP1 | ACHE 2026/4885CCR3 3821/4885OPRM1 29/4885 |
| US-20110172431-A1 | PROCESS FOR PRODUCING 1-SUBSTITUTED TRANS-4-(SUBSTITUTED AMINO) PIPERIDIN-3-OL | TEAD4, TEAD3, TEAD2 | ACHE 3409/4885CCR3 4107/4885OPRM1 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.